Who
5AM Ventures V, L.P.
10% owner
Company insider
Files Form 4 as: 10% owner, Entrada Therapeutics; 10% owner, Rallybio; 10% owner, Cabaletta Bio.
In numbers
- Trades disclosed
- 8
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $11.8M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 7 Sep 2021
- Last trade
- 7 Aug 2026
- Last filed
- 10 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Aug 2026filed 10 Aug 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $358K52,317 at $6.85 | filing |
| 6 Aug 2026filed 10 Aug 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $73K10,494 at $7.00 | filing |
| 31 Jul 2026filed 3 Aug 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $12K1,718 at $6.85 | filing |
| 30 Jul 2026filed 3 Aug 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $795K114,756 at $6.93 | filing |
| 14 Nov 2025filed 18 Nov 2025 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.8M200,000 at $8.80 | filing |
| 8 Feb 2022filed 10 Feb 2022 | RLYB RallybioBiotechnology | SEC FORM 4 Sold | $920K70,461 at $13.05 | filing |
| 8 Feb 2022filed 10 Feb 2022 | RLYB RallybioBiotechnology | SEC FORM 4 Sold | $1.8M139,539 at $13.05 | filing |
| 7 Sep 2021filed 9 Sep 2021 | CABA Cabaletta BioBiotechnology | SEC FORM 4 Sold | $6.1M625,000 at $9.70 | filing |
News
What's Going On With Entrada Therapeutics Stock Wednesday?TRDA · aol.com · 14 Oct 2026Entrada Therapeutics Advances Duchenne Study To Highest Planned Dose LevelTRDA · rttnews.com · 14 Oct 2026Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45TRDA · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name 5AM Ventures V, L.P.; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.